相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: Results of the RECONNECT study
Michael Cronquist Christensen et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2022)
Co-morbidity between mood and anxiety disorders: A systematic review and meta-analysis
Sukanta Saha et al.
DEPRESSION AND ANXIETY (2021)
Expectancy effects on serotonin and dopamine transporters during SSRI treatment of social anxiety disorder: a randomized clinical trial
Olof R. Hjorth et al.
TRANSLATIONAL PSYCHIATRY (2021)
Economic and Humanistic Burden Associated with Depression and Anxiety Among Adults with Non-Communicable Chronic Diseases (NCCDs) in the United States
Eric Arrnbrecht et al.
JOURNAL OF MULTIDISCIPLINARY HEALTHCARE (2021)
Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset
Nadia Iovieno et al.
JOURNAL OF CLINICAL PSYCHIATRY (2021)
Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
Roger S. McIntyre et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2021)
Comorbidity within mental disorders: a comprehensive analysis based on 145 990 survey respondents from 27 countries
J. J. McGrath et al.
EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES (2020)
Depression with high levels of anxiety
Stuart A. Montgomery
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2019)
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Xenia Gonda et al.
EXPERT OPINION ON DRUG DISCOVERY (2019)
Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder
Akira Nishimura et al.
PSYCHIATRY AND CLINICAL NEUROSCIENCES (2018)
Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome
Roxanne Gaspersz et al.
CURRENT OPINION IN PSYCHIATRY (2018)
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Deborah S. Hasin et al.
JAMA PSYCHIATRY (2018)
Efficacy of vortioxetine on the physical symptoms of major depressive disorder
Michael Cronquist Christensen et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Risk factors for relapse and recurrence of depression in adults and how they operate: A four-phase systematic review and meta-synthesis
J. E. J. Buckman et al.
CLINICAL PSYCHOLOGY REVIEW (2018)
The effect of vortioxetine on overall patient functioning in patients with major depressive disorder
Ioana Florea et al.
BRAIN AND BEHAVIOR (2017)
Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder
Yongjie Zhou et al.
SCIENTIFIC REPORTS (2017)
The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine
Clement Francois et al.
CURRENT MEDICAL RESEARCH AND OPINION (2017)
Psychometric validation of the depression and family functioning scale
Valerie Williams et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults
Michael E. Thase et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2016)
A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms
David S. Baldwin et al.
JOURNAL OF AFFECTIVE DISORDERS (2016)
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
David S. Baldwin et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Vortioxetine 10 mg and 20 mg in Adults With Major Depressive Disorder
Paula L. Jacobsen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: A systematic review and meta-analysis
Chi-Un Pae et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2015)
Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data
Connie Sanchez et al.
PHARMACOLOGY & THERAPEUTICS (2015)
A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD
Atul R. Mahableshwarkar et al.
PSYCHOPHARMACOLOGY (2015)
A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder
Atul R. Mahableshwarkar et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2014)
A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine
Stuart A. Montgomery et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2014)
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
Jean-Philippe Boulenger et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder
A. R. Mahableshwarkar et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2014)
Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects
Johan Areberg et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2012)
Development of a family functioning scale for major depressive disorder
Dana Britt DiBenedetti et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: Results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States
Anthony J. Rothschild et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Vortioxetine (Lu AA21004) in generalized anxiety disorder: Results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial
Leszek Bidzan et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder
David S. Baldwin et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2012)
Two-year course of depressive and anxiety disorders: Results from the Netherlands Study of Depression and Anxiety (NESDA)
Brenda W. J. H. Penninx et al.
JOURNAL OF AFFECTIVE DISORDERS (2011)
Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
Benny Bang-Andersen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
ANXIETY DOES NOT PREDICT RESPONSE TO DULOXETINE IN MAJOR DEPRESSION: RESULTS OF A POOLED ANALYSIS OF INDIVIDUAL PATIENT DATA FROM 11 PLACEBO-CONTROLLED TRIALS
J. Craig Nelson
DEPRESSION AND ANXIETY (2010)
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Stuart A. Montgomery et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2009)
Generalized Anxiety Disorder and Psychiatric Comorbidities Such as Depression, Bipolar Disorder, and Substance Abuse
Naomi M. Simon
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report
Maurizio Fava et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach
Gerard Duru et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Assessing treatment effects in clinical trials with the Discan metric of the Sheehan Disability Scale
Kathy Harnett Sheehan et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2008)
Escitalopram in the treatment of anxiety symptoms associated with depression
Borwin Bandelow et al.
DEPRESSION AND ANXIETY (2007)
The role of dopamine in the pathophysiology of depression
Boadie W. Dunlop et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D
M Fava et al.
PSYCHOLOGICAL MEDICINE (2004)
Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression
M Fava et al.
JOURNAL OF AFFECTIVE DISORDERS (2000)
分享论文
